The lipoxin A4 receptor (FPR2/ALX) belongs to the class A rhodopsin G protein-coupled receptor superfamily and plays a role in chemotaxis and activation of phagocytes (1) . Several structurally diverse agonistic ligands, including peptides and lipid mediators have been shown to bind to the FPR2/ALX (2) . Since the discovery of serum amyloid A (SAA) as a proinfl ammatory ligand for FPR2/ALX, more peptides were identifi ed, which all mediate a pro-infl ammatory activation of leukocytes through FPR2/ALX (1) . In contrast, FPR2/ALX can also bind anti-infl ammatory ligands, such as lipoxin A4 (LXA4) and annexin-1 (2) . Indeed, LXA4 was shown to inhibit neutrophil migration, to induce chemotaxis of monocytes and to promote the non-phlogistic phagocytosis of apoptotic neutrophils by macrophages (2) . Thus, FPR2/ALX might induce anti-infl ammatory effects when pro-resolving mediators are present.
Expression of the FPR2/ALX has been observed in several human chronic infl ammatory diseases, such as dermatitis, rheumatoid arthritis, and severe asthma, however, the role of the FPR2/ALX in atherosclerosis has not been investigated (3) .
Atherosclerosis is a multifactorial disease that is characterized by chronic infl ammation at every stage with leukocytes infi ltrating the arterial intima (4) . To investigate the role of FPR2/ALX in atherosclerosis we screened the FPR2/ALX gene for polymorphisms and analyzed whether the detected polymorphisms are associated with coronary artery disease (CAD) in a case-control study involving 497 Caucasians (5, 6) . We initially screened the promoter, the coding region and the 3 ′ region of the FPR2/ALX gene of 98 Caucasians for polymorphisms by DHPLC and detected eight variations, fi ve of which were located in the promoter region, one in the coding region, and two in the 3 ′ region ( Table 1 ) . Seven of these variations proved to be polymorphisms with minor allele frequencies between 5 % and 32 % , while variant c.410G > A was a private mutation. The genotype frequency for all polymorphisms was in agreement with those predicted by the Hardy-Weinberg equilibrium in the case-control sample.
This case-control sample for CAD included 259 patients with > 50 % stenosis in at least one coronary artery and 238 subjects without a history of CAD, stroke, or peripheral vascular disease (5, 6) . Written informed consent was obtained from all participants and the Local Ethics Committee approved the study. The case-control study has a power of 25 % -80 % to detect an OR of 1.7 for minor allele frequencies of 5 % -30 % .
Logistic regression analysis revealed no association between fi ve polymorphisms of the FPR2/ALX gene and CAD (Table 1 ) , while the T allele of the c.-7893C > T polymorphism was associated with an increased risk for CAD (OR = 2.9; confi dence interval 1.2 -7.1; p-value: 0.018). This c.-7893C > T polymorphism is located in the core promoter of the FPR2/ALX gene and could therefore modify the binding site for a transcription factor and hence alter transcription of the gene (8) .
To test whether the C > T transition affects the transcriptional activity of the promoter, we subcloned the FPR2/ALX core promoter upstream of a luciferase reporter gene and introduced all the variations of the minor alleles of the three promoter polymorphisms into individual constructs. These constructs were then transiently transfected into THP-1 macrophages and the transcriptional activity of the different promoter alleles was judged from the intensity of the luciferase reporter enzyme (Figure 1 , dual-luciferase reporter assay) . None of the three polymorphisms c.-7978A > G, c.-7986A > G and c.-7893C > T altered the transcriptional activity of the FPR2/ALX promoter in macrophages, suggesting that the observed association of the SNP c.-7893C > T with CAD was rather a chance fi nding than a real association. This is supported by the skewed distribution of the homozygous TT genotypes between cases and controls in the study sample. While the TT genotype was observed to a low frequency in cases, this genotype was absent in controls (1.95 % vs. 0 % , respectively). The FPR2/ALX haplotypes derived from the seven polymorphisms also showed no association with CAD. DNA extracted from EDTA-supplemented blood was genotyped by tetra-primer analysis for each variation (7) . Association with CAD was analyzed by logistic regression using an additive genetic model adjusted for age and sex. p < 0.05. We observed six haplotypes with a frequency > 1 % which summed up to 94 % of all haplotypes in the sample (data not shown).
In this study, we identifi ed seven polymorphisms in the promoter and in the 3 ′ region of the FPR2/ALX gene, but no polymorphism was detected in the coding region of the gene. Such a lack of polymorphisms in the coding region of the FPR2/ALX gene has previously been observed in a small study comparing the number of polymorphisms in the coding region between the FPR2/ALX and the closely related FPR1 gene (9) . This study found that the two genes originated from a common gene but that they had undergone markedly different evolutionary events since then. While seven polymorphisms have been detected in the coding region of the FPR1 gene in this small Caucasian, Black and Asian sample, no polymorphism was detected in the FPR2/ALX coding region in the same racial groups (9) . Our study supports and expands these fi ndings, because we screened an additional 196 Caucasian alleles and did not fi nd a polymorphism in the coding region of the FPR2/ALX . Such an absence of functional polymorphisms in the coding region and the lack of functional polymorphisms in the core promoter region suggest that the FPR2/ALX gene is highly conserved in humans and that it may be important for the correct function of leukocytes in innate immunity.
In conclusion, the FPR2/ALX gene was not associated with CAD in our small case-control study, however, our study suggests that the FPR2/ALX gene is conserved in humans, since no polymorphism in the coding region and no functional polymorphisms in the core promoter region have been identifi ed.
